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Lymph node (LN) metastases correspond with a worse prognosis in nearly all cancers, yet the
occurrence of cancer spreading from LNs remains controversial. Additionally, the mechan-
isms explaining how cancers survive and exit LNs are largely unknown. Here, we show that
breast cancer patients frequently have LN metastases that closely resemble distant metas-
tases. In addition, using a microsurgical model, we show how LN metastasis development and
dissemination is regulated by the expression of a chromatin modifier, histone deacetylase 11
(HDAC11). Genetic and pharmacologic blockade of HDAC11 decreases LN tumor growth, yet
substantially increases migration and distant metastasis formation. Collectively, we reveal a
mechanism explaining how HDAC11 plasticity promotes breast cancer growth as well as
dissemination from LNs and suggest caution with the use of HDAC inhibitors.
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Metastasis causes ~90% of all cancer-related deaths.Although the most common site of initial spread inmost cancers is to lymph nodes (LNs), which corre-
sponds with a worsened prognosis, the contribution that locor-
egional LN metastasis has on seeding distant organs remains
highly controversial1–3. For example, several large cohort studies
have shown that the presence of microscopic LN metastases
corresponds with poor survival4–6. However, clinical trials
investigating the relationship of LN metastasis treatment with
survival have yielded conflicting results7–9. Furthermore, while
molecular profiling and phylogenetic analyses suggest LN
metastases often give rise to distant metastases in colon cancer
(~35% incidence)10, another study in breast cancer found no
evidence that LN metastases are required for dissemination to
distant sites11. In mouse models, several mechanisms promoting
tumor lymphangiogenesis have also correlated with the devel-
opment of distant metastasis12–15. Recently, the first direct
experimental evidence of LN metastases seeding distant metas-
tases has emerged16–19, which showed that cancer cells egress
from LNs predominantly through the draining LN blood vessels.
However, the mechanistic underpinnings explaining how tumor
cells exit the LN are still unknown. This represents a critical
knowledge gap in metastatic biology20, especially because the
mechanisms governing LN metastasis may be unique from those
promoting direct hematogenous spread from the primary lesion.
Here we show that LN metastases in breast cancer patients
often phylogenetically resemble distant metastases. Using several
experimental models, we show how LN metastasis establishment
occurs through increased expression of a poorly understood
chromatin modifier, histone deacetylase 11 (HDAC11). Interest-
ingly, while genetic and pharmacologic blockade of HDAC11
decreases LN tumor growth, it substantially increases migration
and promotes distant metastasis formation. Our findings
demonstrate that establishment of LN metastasis, and then egress
from LNs to distant sites, is both highly efficient and dynamic.
Additionally, these findings reveal a next context for evaluation of
cancer therapeutics and suggest caution with the use of HDAC
inhibitors (HDACis).
Results
LN and distant metastases share a common origin. Because a
recent report found no evidence that LN metastases were required
for the development of distant metastases in breast cancer11, we
first analyzed a cohort of seven breast cancer patients from the
University of North Carolina Breast Cancer Rapid Autopsy
Program (UNC RAP) for whom primary tumors (T), LN
metastasis (L), and distant metastases (D) were collected21.
Single-nucleotide variant data analysis with pairwise distance
measurements (Jensen–Shannon distances (JSDs))10 was used to
determine whether the LN samples were phylogenetically closer
to the primary lesion or to distant metastases. If in a patient’s
phylogenetic tree we observed that at least one distant metastasis
sample was in the same clade with a LN sample and no other
primary sample, we then concluded it as “LN-met mediated,”
which implies that the LN metastases gave rise to one or more
distant metastases. In all other cases, we concluded it as “LN-met
independent”, which implies that the primary tumor directly
seeded the distant site hematogenously. Compiling a ratio of the
phylogenetic distance between D and L tumors over the phylo-
genetic distance between D and T tumors revealed that five out of
the seven (71%) patients displayed evidence of a LN-met-
mediated spread with at least one distant metastasis (Fig. 1a, b,
d–f), suggesting that distant breast cancer metastases can be
seeded from LN metastases in breast cancer. Bootstrapping ana-
lysis revealed high confidence classification of these clades
(Fig. 1c). In particular, distance ratios for patients A15, A20, and
A34 showed that in some patients there is evidence that distant
metastases in these patients share a more recent common
ancestor with LN metastases than with primary tumors (Fig. 1a,
b, d–f). These results suggest that LN metastases seeded distant
metastases; however, we cannot exclude the possibility that the
distant metastases instead seeded the LN metastases. We also
found evidence for direct hematogenous route of metastasis from
the primary tumor to distant sites, as we also observed in nearly
all patients evidence of distant lesions that were more closely
related to the primary tumors. Two out of seven patients dis-
played only “LN-met-independent” spread (Fig. 1c, g). These
findings suggest that both lymphatic and direct hematogenous
routes of spread commonly co-occur in breast cancer.
LN metastases can give rise to distant metastases. Despite recent
advances in modeling how breast cancer spreads through LN
blood vessels18,19, the mechanisms and potential pharmacological
targets that are involved remain unknown. Much of the com-
plexity stems from the highly interconnected circulatory patterns
of the lymphatic and hematogenous vasculatures22,23. To address
this issue, we utilized a syngeneic mouse breast cancer cell line
(4T1) capable of high-fidelity spontaneous metastases to LNs and
distant organs24. While the 4T1 model histopathologically
resembles triple-negative breast cancer, it also resembles the
luminal molecular subtype25. Starting with the same parental 4T1
line, we generated dual fluorescence and luciferase reporter lines
stably expressing either GFP/firefly luciferase (4T1-G/fL) or
mCherry/Renilla luciferase (4T1-mCh/rL) as a means to analyze
metastasis kinetics. To directly study cells growing in the context
of the LN microenvironment, we developed a micro-injection
model (Supplementary Fig. 1a). This approach allowed us to fine-
tune direct injection into the draining axillary LN (AxLN) and
consistently led to 68% take rates (Supplementary Fig. 1b). These
AxLN tumors grew within the LN capsule similar to spontaneous
AxLN metastases from orthotopic mammary fat pad (MFP)
tumors (Supplementary Fig. 1a, c–e), and showed characteristics
of natural tumor progression, including necrotic regions and
metastasis to the lungs (Supplementary Fig. 1f, g). Using this LN
micro-injection model, we determined the kinetics of distant
metastasis to the lung using flow cytometry by analyzing various
timepoints from 1 day to 6 weeks after AxLN micro-injection
(Supplementary Fig. 2a, b). We found that distant metastases
were readily detected in the lungs by 2 weeks post injection
(Supplementary Fig. 2a).
Dissemination by the lymphatic route is highly efficient.
Considering LNs drain to the lungs via efferent lymphatics or
direct LN blood vessel invasion18,19, we compared the metastases
kinetics from LNs with direct hematogenous seeding by tail vein
injection. Surprisingly, we found that LN tumors were sig-
nificantly more efficient at generating distant metastases based on
both number and frequency of micro-metastases in the lungs and
brain (Supplementary Fig. 2c–f). To compare the metastatic
efficiency of LN tumors with that of primary tumors, we injected
equal cell numbers of 4T1-G/fL into the MFP and 4T1-mCh/rL
into the corresponding right AxLN of the same mouse (Fig. 2a).
The growth of each tumor could be differentiated based on
luciferase signal, and tumor growth rate was similar between the
two cell lines (Fig. 2b, c). After 6 weeks of growth, the vast
majority of the AxLN tumors were mCh+, and <1% of tumor
cells were GFP+, suggesting that distant 4T1-GFP/fL metastases
most likely occurred via the hematogenous route (Fig. 2d). Using
this model, we found that AxLN tumors metastasized to the lungs
more efficiently than orthotopic MFP tumors, as indicated by
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both fluorescence and luciferase signal (Fig. 2e, f). To evaluate
whether the difference in metastatic efficiencies was due to an
intrinsic difference between the two reporter cell lines, we swit-
ched the orientation, micro-injecting 4T1-GFP/fL into the AxLN
and 4T1-mCh/rL into MFP. Again, 4T1-GFP/fL cells injected into
AxLN were more capable of establishing distant metastases in the
lung compared to 4T1-mCh/rL cells injected in MFP (Supple-
mentary Fig. 3a). To better delineate the contribution of hema-
togenous vs. lymphatic dissemination, we also compared injection
of 4T1-mCh/rL cells into either the MFP, the MFP with AxLNs
removed prior to injection, or into the AxLN. Compared with
MFP-injected mice that had AxLNs removed, metastasis to lungs
was significantly increased in the AxLN injection group (Sup-
plementary Fig. 3b). There was no significant difference in lung
metastases (LuMs) between the MFP and the MFP with AxLN
removed groups. Taken together, these data show that distant
metastasis occurs via both hematogenous and lymphatic seeding,
and although hematogenous dissemination is likely the pre-
dominant route of spread, metastasis via LNs is more efficient.
An epigenetic program regulates metastases via the LNs. To
determine how cancer cells spread from LNs, we isolated several
4T1 sub-clones from MFP- and AxLN-injected tumors, and
LuMs that arose from micro-injected AxLNs (AxLN-LuM). After
normalizing to 4T1-mCh/rL and 4T1-GFP/fL parental lines, we
analyzed differentially expressed genes between MFP and AxLN
sub-clones (Fig. 3a), and then between AxLN and AxLN-LuM
sub-clones (Fig. 3b). Based on our analyses, we identified 206
genes that were differentially up- or down-regulated in at least
one of these three microenvironments (Fig. 3c, Supplementary
Fig. 4; see Methods for screening criteria). Gene ontology (GO)
analyses revealed that the genes differentially expression in AxLN
were predominantly involved in cell cycle progression (Fig. 3f).
Consistent with a cell growth phenotype, we found that AxLN
sub-clones divided substantially faster than MFP, AxLN-LuM, or
LuM sub-clones derived from tail vein injections, suggesting an
important role for proliferation within the LN (Fig. 3g). Among
the proliferation regulators, RRM2 and E2F8 were the most dif-
ferentially expressed genes (Fig. 3h). Moreover, of the differen-
tially expressed genes, 152 (74%) were only up- or down-
regulated in AxLN sub-clones, yielding two predominant patterns
of differential expression between MFP, AxLN, and AxLN-LuM
sub-clones: down-up-down or up-down-up (Fig. 3d, e). Based on
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Fig. 1 Metastatic breast cancer patient phylogenetic analysis show that LN metastases efficiently metastasize to distant organs. a Distance ratios from
metastatic breast cancer patient samples on a patient and b individual metastasis basis. c Bootstrap confidence estimates for each group of patient
samples. d–f Representative patient phylogenetic trees showing examples of LN-met- mediated and g LN-met-independent patterns of spread. Light blue
shading demarcates LN-containing clades, whereas dark blue shading demarcates distant metastasis clades. Overlapping shading indicates clades
containing both LN and distant metastases, implicating a LN-mediated pattern of distant metastases. Boxed in metastasis are those displaying a LN-
mediated pattern of spread
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that an epigenetic mode of gene regulation may be involved.
Indeed, chromatin modifiers HDAC11 and EZH1 were sig-
nificantly upregulated in the AxLN clones and were suppressed in
MFP and AxLN-LuM sub-clones (Fig. 3h). We validated several
of these targets by quantitative reverse transcription-PCR (Sup-
plementary Fig. 5a). As both HDACs and histone methyl-
transferases are typically involved in gene repression, we
hypothesized that the increased expression of these epigenetic
regulators in AxLN could be upstream of the genes that were
found to be differentially down-regulated in our analyses. Using
the cancer cell line encyclopedia dataset (n= 1036 cell lines), we
found very strong inverse correlations between expression of
HDAC11 and many of the candidate genes (Supplementary
Fig. 5b), but not EZH1 (Supplementary Fig. 5c). Thus, we focused
on further defining the role of HDAC11 in LN tumor develop-
ment and subsequent spread to distant sites.
HDAC11 is necessary for tumor growth within LNs. HDAC11
is the most recently identified HDAC26, and is best characterized
for epigenetic inhibition of IL-10, which causes pleotropic effects
on innate and adaptive immunity27–29. To determine whether
increased HDAC11 is an artifact of micro-injection, we developed
several matched pairs of sub-clones derived from MFP tumors
and spontaneous AxLN metastases. As compared with corre-
sponding MFP tumors, we found HDAC11 was significantly
increased in five out of seven matched spontaneous AxLN sub-
clones; and expression levels were similar to that of micro-
injected AxLN sub-clones (Fig. 3i). Using six matched primary
tumors and LN metastases from the UNC RAP patient samples,
we used RNA-sequencing data to evaluate HDAC11 expression.
We found that some LN metastases exhibited increased HDAC11
expression compared to the matched primary tumors (Supple-
mentary Fig. 6a, b). However, likely in part due to the small
sample size and dynamic nature of HDAC11 expression, this was
not statistically significant and will require further evaluation in a
larger cohort of clinical samples.
Next, to determine how HDAC11 plasticity is mediated, we
evaluated methylation of the HDAC11 promoter using bisulfite
conversion and found that the HDAC11 promoter was less
methylated in AxLN sub-clones, but had increased methylation in
the MFP and AxLN-LuM sub-clones (Fig. 3j). Because decreased
methylation of the HDAC11 promoter correlated with increased
messenger RNA (mRNA) expression in AxLN sub-clones, these
findings suggest that HDAC11 may itself be epigenetically
modified in the context of the LN microenvironment; however,
it is likely that other mechanisms of gene regulation are involved.
To elucidate the downstream targets of HDAC11, we knocked
down HDAC11 using two different short hairpins RNA
(shRNAs), which resulted in significantly increased mRNA
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Fig. 2 AxLN-micro-injected tumors metastasize efficiently to distant tissues. a Schematic depicting the injection and expected outcomes of GFP/fL- or
mCh/rL-labeled 4T1 cells into the MFP or AxLNs, respectively, of the same mouse. b Representative IVIS imaging of GFP/fL and mCh/rL cells post
injection in the same mouse. c Caliper measurements of tumor growth for MFP and AxLN tumors (n= 7 mice). d Fluorescence imaging of post-injected
AxLNs after 6 weeks of growth show minimal GFP+ cells. e Flow cytometry quantification of lungs and brains to determine relative metastatic capability of
tumors simultaneously established in MFPs and AxLNs. f Ex vivo luciferase signal observed in lungs and brains of mice simultaneously bearing GFP/fL MFP
tumors and mCh/rL AxLN tumors. Statistical significance was measured by Mann–Whitney t tests; **p < 0.01
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and RRM2 (Fig. 4a). Moreover, over-expression of human
HDAC11 in MDA-MB-231 breast cancer or 293 T cell lines,
resulted in significant enrichment of the promoter regions of
these genes by chromatin immunoprecipitation-qPCR (ChIP-
qPCR) when probing for HDAC11 (Fig. 4b, Supplementary
Fig. 7a). To determine whether HDAC11 was functioning as a
HDAC, we used ChIP-qPCR to compare pull-down of acetyl-H3
and acetyl-H4 at the promoters of target genes in 4T1-shCtrl and
4T1-shHDAC11 cells, which revealed significant enrichment of
acetyl-H3 and -H4 at these target gene promoter regions upon
HDAC11 silencing (Fig. 4c). These results were also corroborated
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Fig. 3 LN metastases up- or down-regulate cell cycle-associated genes in a plastic manner. a Pairwise gene expression array comparison between MFP-
and AxLN-implanted tumors. b Pairwise gene expression array comparison between AxLN-implanted and AxLN-derived lung metastases. c Venn diagram
showing shared genes between the analysis of a, b. d Six possible patterns of gene expression across the three experimental conditions (mammary fat pad,
MFP; axillary LN, AxLN; lung metastasis derived from AxLN micro-injection, AxLN-LuM) shown in a, b. e Composite microarray results for the 152 genes
that are up- or down-regulated in both pairwise tissue comparisons (cases 2 and 4 of d). Full 206 gene array shown in Supplementary Fig. 4. f Gene
ontology analysis (biological processes) of the 152 genes displayed in e. g Cell growth assay for the ex vivo clones represented in the microarray analysis.
Statistical significance was measured by unpaired t tests. h Average expression values (RT-qPCR) for several target genes revealed by the microarray
analysis. All statistical comparisons are to the axillary LN tumor samples. Statistical significance was measured by ANOVA. i Relative expression of
HDAC11 between cell lines derived from MFP tumors and matched de novo AxLN metastasis vs. micro-injected AxLNs obtained 1 or 2 weeks post injection.
j Bisulfite sequencing of MFP, AxLN, and AxLN-LuM sub-clones at the HDAC11 promoter CpG island. Statistical significance was measured by unpaired t
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Fig. 4 HDAC11 suppression results in reduced lymph node growth but increased metastasis. a Relative expression of a set of down-regulated array genes
after HDAC11 suppression by shRNA. Statistical significance was measured by ANOVA in comparison to the control shR samples. b Levels of
immunoprecipitated promoter regions for IL-10, RRM2, E2F7, and E2F8 in human MDA-MB-231 cell lines expressing either control or HDAC11 ORFs when
pulling down with either IgG control or HDAC11 antibodies. Statistical significance was measured by ANOVA. c Levels of immunoprecipitated promoter
regions for RRM2, E2F7, and E2F8 in 4T1 cell lines stably expressing either control or HDAC11 shR when pulling down with either IgG control, acetyl-H3, or
acetyl-H4 antibodies. Statistical significance was measured by ANOVA. d Western blots for E2F8 and RRM2 in 4T1 lines expressing control or
HDAC11 shRs. e LN tumor weights at day 35 following axillary LN micro-injection. f Take rates of LN-micro-injected 4T1-shHDAC11 cell lines compared to
4T1-shCtrl cells. P value obtained using a χ2 contingency test. g LN tumor volumes throughout the duration of the experiment (n= 13–14 mice/group).
Statistical significance was measured by unpaired one-sided Student’s t tests. h Lung micro-metastasis enumeration for LN-micro-injected mice by mCh+
flow cytometry. i Lung metastasis index after normalization to LN tumor size (n= 13–14 mice/group). Statistical significance was measured by unpaired
one-sided Student’s t tests (h+ i). j, k Disease-free survival curves from the BreastMark collection comparing patients with high and low levels of RRM2 in
all available breast cancer samples (n= 2652 patients), as well as in LN+ cases (n= 744 patients). Statistical significance was measured by log-rank test.
P values are indicated as *p < 0.05, **p < 0.01, and ***p < 0.001
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E0771.LMB (Supplementary Fig. 7b). Consistent with these
findings, we found increased protein expression of E2F8 and
RRM2 upon HDAC11 loss (Fig. 4d). HDAC11 knockdown also
resulted in significantly reduced colony formation capability in
4T1 cells, suggesting a possible role in tumorigenesis (Supple-
mentary Fig. 8a+b). Similarly, in E0771.LMB cells we found a
dose–response of HDAC11 loss on reduced colony formation
(Supplementary Fig. 8d+e). Based on these findings, we
hypothesized that HDAC11 transiently increases within LNs to
enable tumorigenesis in a hostile, immune-rich microenviron-
ment. In support of this hypothesis, we observed that HDAC11
knockdown exhibited significantly reduced tumorigenicity
(Fig. 4e, f) and growth kinetics (Fig. 4g) following AxLN micro-
injection. Consistent with these findings, we also found that
HDAC11 silencing in E0771.LMB cells resulted in significantly
reduced AxLN tumorigenesis (Supplementary Fig. 8g).
HDAC11 inhibition increased distant metastasis from LNs.
Unexpectedly, the inhibition of HDAC11 led to significantly
increased LuM, especially when normalizing to the reduced AxLN
tumor sizes (Fig. 4h, i). Consistent with these findings,
HDAC11 silencing led to significantly increased migration in
both 4T1 and E0771.LMB cells (Supplementary Fig. 8c+f).
In support of decreased HDAC11 within LNs leading to
increased RRM2 and distant metastasis, functioning as a “release
mechanism,” we found that RRM2 is highly associated with poor
disease-free survival in breast cancer, including patients with LN
involvement at diagnosis (Fig. 4j, k).
Because HDACis are being evaluated in numerous clinical
trials in breast and other solid tumor malignancies, we next
investigated whether pharmacologic inhibition of HDAC11
would yield similar effects on LN tumor growth and metastasis.
Quisinostat is the most potent inhibitor of HDAC11, with sub-
nanomolar potency against HDACs 1, 2, 4 and 1130. We found
that HDAC11, but not HDAC1, 2, or 4, was upregulated in AxLN
sub-clones (Fig. 5a). Treatment with quisinostat resulted in more
significant cell growth inhibition in AxLN vs. MFP sub-clones
with quisinostat (Supplementary Fig. 9a), suggesting that
HDAC11 expression in AxLN sub-clones renders them more
susceptible to HDACi. Quisinostat led to significant induction of
HDAC11 target genes, yet only modest effects on genes
commonly linked with an epithelial–mesenchymal transition
(EMT) (Fig. 5b). Vorinostat and entinostat also led to similar
dose-dependent inductions in HDAC11 target genes in a “cliff-
like” pattern, whereby gene expression increased to a threshold, at
which point considerable cell death was observed and gene levels
dropped (Supplementary Fig. 9b, c). Protein expression of
HDAC11 target genes RRM2 and E2F8 also increased with all 3
HDACis tested (Supplementary Fig. 9d). Based on these results,
we selected sub-lethal HDACi doses that induced HDAC11 target
genes for subsequent experiments (termed “sub-lethal” doses).
Next, we tested the effect of sub-lethal HDACi-treatment on 4T1
growth and motility. While colony formation was considerably
impeded (Supplementary Fig. 9e), transwell migration signifi-
cantly increased following treatment with quisinostat, which we
confirmed in E0771.LMB cells as well (Fig. 5c, d). To test the
effect of quisinostat treatment on LN tumor growth and
metastasis, we micro-injected AxLNs with 4T1-mCh/rL cells.
After sub-palpable tumors were established as determined by
luciferase signal, mice were randomly distributed and treated with
either vehicle or quisinostat. Although quisinostat treatment
significantly inhibited AxLN tumor growth, based on luciferase
imaging and caliper measurements (Fig. 5e, f), quisinostat
treatment significantly increased LuM (Fig. 5g). Notably,
considering the differences in AxLN tumor size, quisinostat
increased metastasis by over 5-fold (Fig. 5h). To determine
whether these results were related to the effects of quisinostat on
the host vs. a cancer cell autonomous mechanism, we performed
an experimental metastasis assay in which 4T1-mCh/rL cells were
treated in vitro for 2 weeks with vehicle or quisinostat. No
difference in micro-metastasis was seen at 24 h, whereas the
quisinostat-treated cells formed significantly more LuMs by
1 week, based on mCh+ counts and hematoxylin and eosin
(H&E) staining (Fig. 5i, j). Furthermore, quisinostat pre-
treatment increased the average size of the lung micro-
metastases (Fig. 5k), perhaps related to an increased number of
pro-migratory cells extravasating and forming distant metastatic
colonies. Importantly, the increased metastases were not due to a
“rebound effect” as has been reported for other therapeutic
agents31, as quisinostat withdrawal resulted in colony formation
rates that were similar to vehicle-treated cells (Supplementary
Fig. 9f). We observed similar increases in metastatic character-
istics using sub-lethal doses of vorinostat and entinostat, both of
which significantly impaired cell proliferation and colony
formation, but led to significantly increased migration and
experimental LuM formation (Supplementary Fig. 9g–j).
Although these results corroborate the phenotypes observed with
genetic knockdown of HDAC11, these pharmacologic inhibitors
are not HDAC11-specific and may be affecting other HDACs.
Thus, it is likely that other HDACs are also involved in the
phenotypes observed.
Discussion
In nearly all cancer types, the presences of LN metastases are
clinically significant and hold great prognostic power. Yet, until
recently, there was no experimental evidence that LN metastases
could give rise to distant metastases18,19. Collectively, using
phylogenetic analyses of clinical samples and direct experimental
models, our results show that breast cancer LN metastases can
give rise to distant metastases. Our findings that the lymphatic
route is highly efficient to give rise to distant metastasis carries
therapeutic implications, as almost all pre-clinical models assume
that cancer metastasizes by direct intravasation into and then
extravasation out of blood vessels. The limited success of anti-
angiogenic therapies in patients suggests that current experi-
mental models are not fully recapitulating the metastatic process,
which may in part be because lymphatic metastases are largely
ignored. Recently, it was found that anti-angiogenic therapies
have little effect on LN metastases, and some anti-angiogenic
therapies may even promote LN metastases formation32,33.
Herein, we have also identified a mechanism by which dis-
semination through LNs occurs. We demonstrate that increased
expression of a chromatin modifier, HDAC11, is important for
tumorigenesis and growth within the LN, but that subsequent
downregulation of HDAC11 in the LN results in increased
migration and egress from LNs to distant sites. We found that
HDAC11 inhibits E2F7 and E2F8, which are widely regarded as
cell cycle suppressors34, and this may in part explain HDAC11’s
role in promoting cancer cell survival within LNs (Fig. 6, top).
Additionally, we found loss of HDAC11 leads to de-repression of
RRM2. We posit that this increase in RRM2, which has been
linked to pro-migratory and metastatic phenotypes in many
cancers, including breast cancer35, functions as a release
mechanism from the LN to distant sites (Fig. 6, bottom).
In breast cancer, aberrations in histone modifications like
acetylation have been shown to be important for tumor pro-
gression and prognosis, and have been proposed as a promising
therapeutic target36–38. HDACis have been an attractive ther-
apeutic strategy to both restore acetylation and gene expression
with the potential benefit of being better tolerated than cytotoxic
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Fig. 5 Pharmacological HDAC inhibition reduces cell and tumor growth, but increases cell migration and tumor metastasis from LNs. a HDAC mRNA
expression levels from ex vivo 4T1 clones. b Target gene E2F7, E2F8, and RRM2 and EMT marker expression levels after quisinostat treatment.
c, d, Transwell migration assay for 4T1 (c) and E0771-LMB (d) TNBC cells. e Intravital imaging of LN tumors of mice implanted with 4T1-mCh/rL cells.
f Tumor volumes for LN-micro-injected tumor-bearing mice treated with vehicle or quisinostat (40mg/kg; twice weekly). g Enumeration of lung micro-
metastases in LN-micro-injected tumor-bearing mice after 6 weeks. h Metastasis index of vehicle- and quisinostat-treated mice after normalization to LN
tumor size (n= 10 mice/group for f–h). i Enumeration of lung micro-metastases after in vitro-treated vehicle or quisinostat 4T1-mCh/rL cells were injected
by the tail vein. j H&E staining of stitched left lungs from tail vein-injected mice. The graph shows the average number of tumors per lung for vehicle- and
quisinostat-treated mice. k Representative H&E-stained images of lung lesions from vehicle- and quisinostat-treated mice. The graph shows individual
tumor diameter measurements. Statistical significance was measured by unpaired one-sided Student’s t tests, unless otherwise indicated; p values are
indicated as *p < 0.05, **p < 0.01, and ***p < 0.001
Pro-growth within lymph node







Fig. 6 Graphical abstract of HDAC11’s role in regulating lymph node metastasis. As cancer cells enter the lymph node (top), HDAC11 increases in
expression, leading to decreased expression of several transcripts and increased survival within the lymph node. However, as HDAC11 decreases (bottom),
the same transcripts increase in expression, leading to an increased migratory phenotype and allowing exit from the lymph node to distant organs. Thus,
pharmacologic inhibition of HDAC11 may decrease cancer cell survival within lymph nodes while also increasing their migratory capabilities
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chemotherapy. Epigenetic modulation has also been hypothesized
to be a mechanism of resistance to endocrine therapies and
cytotoxic chemotherapy39. Despite the promising anti-tumor
effects of quisinostat and other HDACis in pre-clinical models30,
when used as monotherapy it has had limited activity thus far in
patients40. Our results highlight the importance of evaluating
candidate therapeutics in the context of LN metastasis, as well as
the unique challenge of targeting plasticity in metastasis3. Similar
to how blocking the EMT may simultaneously prevent detach-
ment from the primary tumor and yet also promote metastatic
colonization by inducing a mesenchymal-to-epithelial transition
(MET), we demonstrate that the spectrum of HDAC11 expres-
sion along the metastatic cascade may have opposing effects if
inhibited. Given the active investigation and development of
multiple HDACis in cancer patients, our results strongly advise
caution in the single-agent use of HDACi in the treatment of
breast cancer and potentially other solid tumors.
METHODS
Cell lines and key reagents. 4T1 cells were obtained from the ATCC and
maintained in RPMI containing 10% fetal bovine serum (FBS). EO771.LMB cells
were generously provided by Dr. Robin Anderson (Peter MacCallum Cancer
Center). 4T1 cells were transduced with lentiviral constructs expressing either GFP/
FL or mCherry/Renilla luciferase, which were obtained from Dr. Shawn Hingtgen
(UNC) and were selected and maintained in puromycin (8 μg/ml). 4T1-
shHDAC11 cell lines were selected and maintained in hygromycin (50 μg/ml).
FLAG-HDAC11 was provided by Dr. Alejandro Villagra (George Washington
University). Quisinostat, vorinostat, and entinostat were purchased from Sell-
eckchem (S1096, S1047, and S1053, respectively). Small interfering RNAs (siRNAs)
targeting HDAC11 were obtained from Sigma (siHDAC11 #1: CUAUCAAGUUC
CUGUUUGAdTdT; siHDAC11 #2: GUGACAAGCGAGUAUACAUdTdT).
shRNA constructs targeting HDAC11 were obtained from Genecopoeia
(shHDAC11 #1: gctactcacagaacattgtca; shHDAC11 #2: ggaccactggaaataaagatt). All
cells were routinely tested for mycoplasma using a Lonza MycoAlert Detection kit
(LT07-418). Adult female Balb/c mice (6–8 weeks) were purchased from Taconic
Farms. All animals were cared for according to guidelines set forth by the
American Association for Accreditation of Laboratory Animal Care and the US
Public Health Service policy on Human Care and Use of Laboratory Animals. All
mouse studies were approved and supervised by the University of North Carolina
at Chapel Hill Institutional Animal Care and Use Committee.
Rapid autopsy analysis. From the UNC Breast Cancer Rapid Autopsy Program,
all clinical samples were obtained and prepared following informed consent and
institutional review board approval for UNC Chapel Hill. We obtained the next-
generation sequencing data for seven breast cancer patients for whom at least one
primary tumor sample, one LN metastasis sample, one matched normal tissue, and
multiple distant metastases samples were collected as previously described21.
Samples with lower tumor purity were excluded from further analysis. Integrated
DNA and RNA variant calling pipelines41,42 were used for variants calling followed
by a computational re-interrogation step to improve mutation calling sensitivity
while keeping low false positives. Using all detected somatic mutations for each of
the seven patients, we calculated a pairwise distance between sample pairs via the
JSD using the R software package “phyloseq.” The distance matrices reflected how
many mutations of each sample diverged from the other. To determine whether the
LN sample is closer to the primary or to the distant metastases in each patient, we
calculated a distance ratio for each LN sample. The ratio is defined as DLM/DLP,
where DLM is the shortest distance between the LN and any other distant metastasis
and DLP is the distance between the LN and the primary sample in the same
patient. Similarly, we used the DML/DMP ratio to determine whether a distant
metastasis is closer to a LN sample (ratio < 1) or closer to a primary sample
(ratio > 1), where DML is the distance between the distant metastasis sample and
the LN sample, and DMP is the distance between the distant metastasis sample and
the primary sample in the same patient. The distance matrices were also used to
construct a phylogenetic tree via the neighbor-joining algorithm (using the R
software package “ape”), which produce un-rooted trees. When plotting rooted
trees, we put the primary sample as its root.
In each patient, we also classified it into either “LN-met mediated” or “LN-met
independent” using the same rule from ref. 10. From each patient’s rooted
phylogenetic tree, if we observed a clade with only distant metastasis sample(s) and
a LN sample then we concluded it as “LN-met mediated”. If we do not find such
cases, we concluded it as “LN-met independent.”
To check the robustness of such origin classification, we performed
bootstrapping of the mutation data for each patient to determine whether the
origin classification was sensitive to changes in a limited number of somatic
mutations. For each patient, we performed repeated random sampling of the
mutation data 1000 times. In each iteration, we computed the distance matrices
and classified the patient into one of the two origin classifications as described
above. We then assigned a confidence score to each patient, where the confidence
score is the number of times the classification is the same as the real origin
classification divided by 1000 (number of iterations) multiplied by 100.
Microarray analyses. Two plates of Mouse Gene 2.1 ST Affymetrix oligonu-
cleotide microarrays were hybridized using (i) two baseline samples (i.e., 4T1-GFP-
fLuc and 4T1-mCherry-rLuc), each available as a quadruplicate (four biological
replicates), together with the other experimental samples, each available as a tri-
plicate (three biological replicates). The selected experimental samples, which are
shown in Fig. 2, were derived from: (1) MFP, injected in and extracted from MFP;
(2) AxLN, injected in and extracted from AxLN; (3) AxLN (-derived) LuMs
(AxLN-LuM), injected in AxLN and extracted from LuMs. Each sample was
obtained at different timepoints; for the sake of brevity, and since we were looking
for experimental evidence of time-independent gene regulation, each of these cases
is called in this paragraph a “sample type.” The generation (starting from the raw
data) and normalization of the RNA expression values was performed using the
robust multi-array algorithm43,44. The expression values of these two plates were
scaled, according to the ratio of cumulative gene expression of each plate, and then
combined into one spreadsheet. Then, the whole set of RNAs was reassessed, so
that only those (i) fulfilling minimum and not conflicting annotation criteria
(including predicted RefSeq, NCBI Reference Sequence Database: http://www.ncbi.
nlm.nih.gov/refseq/] genes and GenBank [NIH Genetic Sequence Database: http://
www.ncbi.nlm.nih.gov/genbank/] genes having an associated gene symbol) and (ii)
annotated as protein-coding genes, were analyzed.
We deemed differentially expressed (vs. the baselines) genes: (i) whose average
expression value for at least one sample triplet was ≥50% or ≤50% than the average
in the two available baselines; (ii) ≥25th percentile in terms of range (across the
samples) of the sub-matrix containing the baselines and that sample triplet, and
(iii) for which each comparison between the three samples of that triplet and the
baseline replicates maintained the same polarity (> or <). Afterwards, we directly
compared different sample types. The comparisons performed were: (i) MFP vs.
AxLN, (ii) MFP vs. AxLN-LuM, and (iii) AxLN vs. AxLN-LuM. The results of
these comparisons (based on the third point above illustrated for determining
genes differentially expressed) were displayed separately. Of course, no other
comparisons were possible, since AxLN vs. MFP is equivalent to MFP vs. AxLN,
and so on. Because of the way in which genes are selected before being displayed
through heat maps as well as of simple combinatorics calculations, the p values
specifically associated with each gene identified by (i), (ii), and (iii) are, respectively,
1.9980e− 04, 1.9980e− 04, and 2.0568e− 05. At this point, we looked for patterns
of gene expression across these three sample types, that is, for the set MFP-AxLN-
AxLN-LuM, by merging these three heat maps. Every time an array RNA was
shared between two of these three heat maps, it was kept in the merged heat map
that displays the three sample types. This step was repeated three times, that is, as
many as the possible couples of heat maps to be matched. Overall, the possible
patterns of gene expression using a vocabulary containing only the words “Up” and
“Down” are: (a) Up-Up-Down, (b) Down-Down-Up, (c) Up-Down-Down, (d)
Down-Up-Up, (e) Up-Down-Up, and (f) Down-Up-Down. Cases a and b are
considered as pattern/anti-pattern, and the same is true for cases c and d and for e
and f. Due to the chosen criteria, after RNAs are collected for the heat map MFP-
AxLN-AxLN-LuM following this computational protocol, it is still necessary to run
an additional algorithm for associating possible genes belonging to multiple
patterns to their strongest gene expression pattern. This additional algorithm
assumes that when a gene reaches its highest average expression in a sample type,
then that sample type receives the tag Up for that gene. Similarly, when a gene
reaches its lowest average expression in a sample type, then that sample type
receives the tag Down for that gene. Finally, the sample type having an
intermediate average expression level is tagged as Up or Down for that gene
measuring its distance from the other two sample types and assuming that if the
minimum distance is from the ‘Up’ sample type, the sample belongs to the ‘Up’
sample type too, while if the minimum distance is from what is tagged as Down,
the sample type is tagged as Down too. The distance d used for this purpose is such
that if xi ε X and yj ε Y, with 1 ≤ i ≤ p and 1 ≤ j ≤ q, p and q positive integers, then d
(X, Y)=mini,j(|xi− yj|); in our case, p= q= 3. Notably, in this computational
framework, all the samples of a sample type are always tagged with the same tag
with respect to an included gene and algorithm-based tagging is separately made
for each gene. At the end of these steps, it was possible to univocally calculate how
many genes belong to each of these patterns for MFP-AxLN-AxLN-LuM.
Later, the three couples of patterns/anti-patterns for the sample set MFP-AxLN-
AxLN-LuM were separated and plotted in three distinct heat maps. Each
hierarchical clustering was performed with respect to the matrix rows (containing
the gene expression values across all samples) on log 2-trasformed, mean-
subtracted data, using open source clustering software45,46. Each heat map was
then split into its top and bottom parts, looking at the couple of genes of the heat
map where a change of sign in the corresponding cdt file was present for the
“divergent” sample type. We call “divergent” the sample type whose pattern tag is
different from the other two (e.g., in the pattern c, Up-Down-Down, the divergent
sample type is the first, MFP). In particular, the last gene having a specific sign
across the divergent samples in the cdt file was considered the last gene of the “top”
part and the first gene having the opposite sign was considered the first of the
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“bottom” part. After this step, genes belonging to each half were separately
processed using the Expression Analysis Systematic Explorer score (a p value
derived from an adjusted Fisher’s exact test) and through DAVID bioinformatics
resources47,48 for mouse genes, looking for GO terms of biological processes that
were statistically significant (p value < 0.01).
Breast cancer clinical outcome analysis. To determine clinical relevance of
RRM2 expression in breast cancer subtypes, we utilized the BreastMark public
microarray database of mRNA expression and clinical annotations, which has been
previously described49. The median threshold was used to distinguish high (above
median) and low (below median) expression of RRM2. Disease-free survival ana-
lysis was determined using the log-rank test for all patients (inclusive of luminal A,
luminal B, Her2+, basal-like and normal-like subtypes) and for patients with
positive LNs at the time of diagnosis.
Real-time qPCR. After treatment, RNA was purified from cells using the Zymo
Quick RNA miniprep kit according to the protocol recommended by the manu-
facturer (Zymo Research, R1057). Then, complementary DNA (cDNA) was syn-
thesized using a Bio-Rad iScript cDNA synthesis kit (1708891) for total RNA.
cDNA was analyzed using SYBR Green reagent (Bio-Rad, 1525271) according to
the protocol recommended by the manufacturer. PCR was done with reverse-
transcribed RNA, 1 μL each of 20 μM forward and reverse primers, and 2× Pow-
erUp SYBR Green Master Mix in a total volume of 25 μL. Data were analyzed using
the ΔΔCt method, and experiments were normalized to 18S rRNA. Primer
sequences included the following: Hdac11—forward (Fwd), AATGGGGCAAGG
TGATCAAC and reverse (Rev), GCCACCACAAAGGACCACT; Rrm2—Fwd,
ACGACCTCAACGCACAGTACG and Rev, GTAAGGGCAGGAGTCCCATGA
TG; E2f7—Fwd, GATGCGTTCGTGAACTCCCTG and Rev, AGAAACTTC
TGGCACAGCAGCC; E2f8—Fwd, GAGAAATCCCAGCCGAGTC and Rev,
CATAAATCCGCCGACGTT; Plk1—Fwd, GTC AGAACCCATGCGGCAGCAAG
and Rev, CAGGTCCACATGGTCTTCCTCTG; Hdac1: Fwd, AGTCTGTTACT
ACTACGACGGG and Rev, TGAGCAGCAAATTGTGAGTCAT; Hdac2—Fwd,
GCTTGCCATCCTCGAATTACT and Rev, GTCATCACGCGATCTGTTGTAT;
Hdac4—CACTGCATTTCCAGCGATCC and Rev, AAGACGGGGTGGTTGTA
GGA; Cdh1: Fwd, CAGGTCTCCTCATGGCTTTGC and Rev, CTTCCGAAAAG
AAGGCTGTCC; Zeb1—Fwd, GCTGGCAAGACAACGTGAAAG and Rev, GCC
TCAGGATAAATGACGGC; Zeb2—Fwd, GCTACACGTTCGCCTACCG and
Rev, CCTTGGGTTAGCATTTGGTGC; Twist—Fwd, GGACAAGCTGAGCAAG
ATTCA and Rev, CGGAGAAGGCGTAGCTGAG; 18S—Fwd, AGAAAATCTG
GCACCACACC and Rev, CTCCTTAATGTCACGCACGA; GAPDH—Fwd,
CCTGACCTGCCGTCTAGAAAAACCT and Rev, CCATGAGGTCCACCA
CCCTGTT. Reactions were run on a QuantStudio 6 or a StepOnePlus qPCR
machine (Applied Biosystems), and cycling conditions consisted of 15 s of dena-
turation at 95 °C and 1min of annealing and extension at 60 °C (40 cycles).
Reactions were run in triplicate.
Western blotting. Cells were lysed in 0.5% Nonidet P-40 or 2% SDS. Immediately
before lysis, 1x protease inhibitor cocktail (leupeptin L2884, aprotinin A1155,
benzamidine B6506, trypsin inhibitor T9003, all from Sigma), 1 mM phe-
nylmethylsulfonyl fluoride (PMSF, Sigma P7626), 1 mM NaVO3 (Fisher Scientific
S454-50), and 1 mM dithiothreitol (DTT, Roche 03117014001) was added to the
lysis buffer. An equal amount of total protein for each sample was loaded onto
4–20% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) gradient gels. After
separation, proteins were transferred to nitrocellulose membranes using a Bio-Rad
tank transfer apparatus. Membranes were blocked in 5% non-fat milk in
phosphate-buffered saline (PBS) with 0.1% Tween-20 (PBS-T) for 1 h at room
temperature, after which primary antibody was added and incubated at room
temperature for 2 h or overnight at 4 °C. Anti-RRM2 was purchased from Novus
Biologicals (1:1000, NBP131661), anti-E2F7 was purchased from Novus (1:1000,
NBP1-80266), anti-E2F8 was purchased from Novus (1:1000, NBP152650), and
anti-vinculin was purchased from Sigma (1:1000, V9131). Membranes were washed
in PBS-T, after which membranes were incubated with secondary antibody at room
temperature for 1 h. Membranes were washed with PBS-T, and then bands were
developed using ECL reagent (Bio-Rad, Hercules, CA). Images were acquired using
a Bio-Rad digital imager (Bio-Rad, Hercules, CA).
Chromatin immunoprecipitation qPCR. ChIP assays were conducted using the
Active Motif kit (Novus Biologicals, Littleton, CO) according to the protocol
recommended by the manufacturer with a few adaptations for HDAC11 immu-
noprecipitation (IP). HEK293T, MDA-MB-231 cells transfected with control or
HDAC11-ORF, and 4T1 and EO771.LMB cells stably expressing shCtrl or
shHDAC11#1 were cultured in 10-cm dishes, after which cells were incubated with
1% formalin at 37 C for 10 min. Formalin was neutralized with glycine, and then
the cells were washed twice with cold PBS. Cells were scraped in cold PBS, pelleted,
and resuspended in 1 mL of sodium dodecyl sulfate lysis buffer. DNA was soni-
cated using a Diagenode Bioruptor and then precleared with protein-A/G agarose
beads. Precleared DNA was subjected to IP with 10 μg of antibody (IgG, anti-
HDAC11 (both Sigma, H4539 and BioVision, 3611P were used together), anti-
acetyl-H3 (Millipore 06-599), or anti-acetyl-H4 (Millipore 06-598) by rotating at
4 °C overnight. Antibody/DNA complexes were pulled down by incubation with
protein-A/G beads at 4 °C for 1 h. Beads were washed, and then antibody–DNA
complexes were eluted from the beads. Cross-links were reversed with 200 mM
NaCl incubated at 65 °C overnight. Samples were RNase-treated and then incu-
bated with 10 mM EDTA, 25 mM Tris-HCl (pH 6.5), and 20 mg/mL proteinase K
for 1 h at 45 °C. DNA was purified using a Qiagen QIAQuick PCR purification kit,
and then DNA was quantified using qPCR. Primers for ChIP-qPCR included the
following: (human) E2F7—Fwd, GCTGATTGGTGGATTCTCAA and Rev,
GGATCGTAGTCCCCGCTAA; E2F8—Fwd AACTTTTCCCCCAACTCTGC and
Rev CCCCCGATTTGAAATTAACC; RRM2—Fwd, GCTCTCCTCACCGCATTA
AC and Rev—ACAAGCGACCAGGCTTCTTA; PLK1 and Fwd—GTCCGTGT
CAATCAGGTTTTC and Rev, GCTGGGAACGTTACAAAAGC; TIPIN—Fwd,
CTTTCCACACTCCCACTCG and Rev, GACGTATTTCCGCGTCATCT; CDC7
—Fwd, GAAGAAACCCCACCCTCTTG and Rev, CTCCAAGAGATCCCCACC
TAC; CDC25A—Fwd, CTGATTGGTGGATTCCGTTT and Rev, CACCTCTTA
CCCAGGCTGTC; ESPL—Fwd, AGCCGCGGATATTTGAAAG and Rev, ACAGG
ACTTAACCGCCTGAC; MCM3—Fwd, AACAGAGAATCCCGGATGGTA and
Rev, CTGAGTTCTCTGAGGTCGGACT; IL-10—Fwd, ATAAAAGGGGGACAG
AGAGGTG and Rev, GCCTTCTTTTGCAAGTCTGTCT.
(Mouse) E2F7—Fwd, TTGCAAAACCCCCTTTGGTG and Rev, ACGTGAAC
CCTGGTTAGCAC; E2F8—Fwd, AAGAGCCCAAACCACAATCTTA and Rev,
AGTTAGGAGACCATCTCGTCCA; RRM2—Fwd, CAACTCAAATCTCCCGC
GCT and Rev, TTAAAGAGCCACCCAACCGC.
Transfection. 4T1 cells were plated at 40% confluency in 6-well plates, after which
the cells were transfected with siHDAC11 or siCtrl duplexes (60 nM final con-
centration; Sigma, St. Louis, MO) using RNAiMAX according to the protocol
recommended by the manufacturer. The transfection was conducted for the
indicated amount of time before the cells were collected and analyzed. The fol-
lowing siRNA constructs were used (sense strand displayed): siCtrl, UUCUCCG
AACGUGUCACGUdTdT; siHDAC11-1, CUAUCAAGUUCCUGUUUGAdTdT;
siHDAC11-2, GUGACAAGCGAGUAUACAUdTdT.
Virus packaging and transduction. Viral particles were produced by transfecting
human embryonic kidney cells (HEK293T cells) with lentiviral vector, packaging
plasmid (psPAX2), and envelope plasmid (pMD2G). Media were changed the next
day, and 2 days later, viral supernatant was collected and filtered to remove cellular
debris. For infection, 4T1 cells were plated in 6-well plates at 40% confluency.
Then, viral particles were added to the cells in the presence of 8 μg/ml Polybrene.
After overnight infection, the media were refreshed. Hygromycin (50 μg/ml) or
puromycin (8 μg/ml) was added to the media to select for transduced cells.
HDACi treatment. 4T1 cells were treated in 10-cm tissue culture dishes at the
indicated concentration of drug (dissolved in dimethyl sulfoxide). Media and drug
were refreshed daily to ensure consistent drug exposure. For long-term treatment,
cells were exposed to HDACis for at least 7 consecutive days. The sub-lethal dose
for quisinostat in 4T1 cells was determined to be 10 nM, whereas vorinostat was
500 nM and entinostat was 2 μM. For the quisinostat withdrawal experiment, cells
that were treated long term with 10 nM quisinostat were seeded into complete
RPMI without the drug for colony formation capability or for testing subsequent
passages in drug-free medium for colony formation capability.
Haptotaxis/chemotaxis migration assays. A total of 25,000 or 50,000 cells were
added in serum-free medium to Boyden chambers (8-μm pores) that were pre-
coated with 10 μg/ml type 1 rat tail collagen on the bottom of the inserts. RPMI
medium containing 10% FBS was added to the lower chambers as the chemoat-
tractant. Haptotaxis/chemotaxis was allowed to proceed for 18 h, after which cells
were removed from the top chambers, and cells migrated to the bottom of the filter
were fixed and stained using the Protocol Hema 3 staining kit (Fisher Scientific,
22122911). Membranes were mounted onto glass slides, and images were taken
using a Nikon microscope. Migrated cells were enumerated using CellProfiler open
source image analysis software (CellProfiler).
Cancer cell implantation. Adult Balb/c mice were purchased from Taconic Farms
and C57Bl/6 mice were purchased from Jackson Labs. These animals were cared for
according to guidelines set forth by the American Association for Accreditation of
Laboratory Animal Care and the US Public Health Service policy on Human Care
and Use of Laboratory Animals. All mouse studies were approved and supervised
by the University of North Carolina at Chapel Hill Institutional Animal Care and
Use Committee. All animals used were between 6 and 10 weeks of age at the time
of injection. For all animal experiments, cells were trypsinized, washed, and
resuspended in Hank’s balanced salt solution (HBSS; Gibco) prior to injection.
Mammary fat pad: Cells were trypsinized and suspended in Matrigel at a 1:1
ratio, and 5000 cells were injected directly into the eighth MFP of anesthetized
6–10-weeks-old female Balb/c mice. Caliper measurements of subcutaneous tumor
growth were taken twice weekly and the tumor volume was calculated as L ×W2,
where L is the greatest cross-sectional length across the tumor and W is the length
perpendicular to L. Luciferase-labeled tumor progression was monitored once
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weekly using an IVIS Lumina optical imaging system and Nano-Glo Luciferase
Assay substrate (Promega) as per the manufacturer’s instructions.
Axillary LN: Mice were anesthetized, depilated, and subjected to surgical
implantation of 5000 (4T1) or 4 × 104 (EO771.LMB) cells in a total volume of 1 μl
HBSS. Injections were performed using a dissecting microscope and a 10-μl
Hamilton syringe and custom-made microtip Pasteur pipette. Caliper
measurements of tumor growth were taken twice weekly, and the tumor volume
was calculated as L ×W2, where L is the greatest cross-sectional length across the
tumor and W is the length perpendicular to L. Luciferase-labeled tumor
progression was monitored once or twice weekly using an IVIS Lumina optical
imaging system and RediJect Luciferase Assay substrate (Promega) as per the
manufacturer’s instructions. Metastasis index was determined by dividing the
number of mCh cells identified by flow cytometry by the average size of the
primary AxLN tumor.
Tail vein: Mice were injected with 5 × 103 or 1 × 105 4T1 cells in HBSS by tail
vein, after which mice were monitored daily for health. Mice were sacrificed and
analyzed at the indicated time point post injection.
Ex vivo cell line establishment and analysis. Tumors were excised (under aseptic
conditions for propagation) in a laminar flow tissue culture hood and minced using
a sterile scalpel blade in digestion medium. For direct analysis, tissue was minced
using scissors. Minced tissue was digested for 1 h in 0.125% collagenase II, 0.1%
hyaluronidase, 15 U/ml DNase, and 2.5 U/ml dispase. Cells were then pelleted,
subjected to ACK red blood cell lysis, and then pelleted and analyzed by flow
cytometry or plated in 10-cm dishes containing complete RPMI medium and
antibiotics as appropriate. For passaging and subsequent culture, ex vivo 4T1 sub-
clones were selected with 6-thioguanine for several days until pure colonies were
observed.
Flow cytometry analysis. Fluorescently labeled 4T1 cells were stained with Live/
Dead fixable violet dye (Thermo Scientific) for 15 min, after which cells were
washed and suspended in FACS buffer (1% bovine serum albumin in PBS con-
taining 0.5 mM EDTA). Then, cells were analyzed using a Cyan (Beckman Coulter)
or Attune NxT (Life Technologies) flow cytometer. FCS files were analyzed using
FlowJo software (version 10; FlowJo LLC).
H&E staining. Tissues were fixed in 10% buffered formalin for at least 24 h, after
which they were embedded in paraffin and sectioned in 4–5 μm sections. Sections
were mounted onto Fisher Superfrost Plus slides and then deparaffinized and
stained with H&E by the UNC Animal Histopathology Core. Stained slides were
imaged using a Leica DMi8 inverted microscope at ×200 magnification. Images
were scored using CellProfiler open source image analysis software (CellProfiler).
Tumor diameters were measured manually by counting pixels for the largest dia-
meter of each identified tumor.
Colony formation assay. After treatment, cells were trypsinized, counted, and
1000 or 5000 cells were plated in triplicate in 6-well plates containing complete
RPMI medium and drug, as indicated. Cells were allowed to grow under standard
conditions for at least 4 days until colonies were observed. For staining, 1 ml of
crystal violet stain (0.05% crystal violet, 1% formalin, 1% methanol in PBS) was
added to the cells. Cells were destained in deionized water, and images were taken
using an Epson office scanner under film settings. To quantify stain, crystal violet
was extracted using 1.5 ml of 1% SDS, followed by absorbance measurement at 612
nm wavelength light on a BioTek luminometer plate reader. Readings were also
conducted in triplicate for each sample.
DNA methylation detection. Bisulfite-converted DNA was generated and purified
from 4T1 sub-clones using the EZ DNA Methylation-Direct kit (Zymo Research).
Bisulfite-converted DNA was then amplified by PCR using primers designed with
the assistance of MethPrimer50: Fwd, GGTTAGAGTTTTATTTTTAGTTTTTAG;
Rev, CTACAAAAAACTATACCCTCCTC.
PCR products were purified (Qiagen QIAquick PCR Purification kit) and then
directly DNA sequenced (Eton Bioscience).
Statistical analysis for in vitro and in vivo experiments. Between 5 and 15 mice
were assigned per treatment group; this sample size gave ~80% power to detect a
50% change in tumor weight with 95% confidence. Results for each group were
compared using Student’s t test (for comparisons of two groups) and analysis of
variance (for multiple group comparisons). For values that were not normally
distributed (as determined by the Kolmogorov–Smirnov test), the Mann–Whitney
rank-sum test was used. A P value < 0.05 was deemed statistically significant. All
other statistical tests for in vitro and in vivo experiments were performed using
GraphPad Prism 7 (GraphPad Software, Inc., San Diego, CA). The multiple
hypothesis testing correction of these results was made using the false
discovery rate.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The microarray data that support the findings of this study have been deposited in the
Gene Expression Omnibus (GEO) data bank, accession code (GSE136031).
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